Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Ease GCP Ordinance in Line with ICH-GCP, Promote Clinical Trials
May 7, 2012
- 1st Committee on Drugs Recommends Approval for MTPC’s DPP-4 Inhibitor Teneligliptin
May 7, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (2)
May 2, 2012
- Interview with PMDA Chief Executive Tatsuya Kondo (1)
May 1, 2012
- DPJ's PAL Subcommittee to Finalize Reform Proposal in May, Some Recommendations to Be Reflected in Economy Revival Strategy
April 27, 2012
- CSIMC to Establish Expert Subcommittee on Cost-Effective Assessments, 1st Meeting Scheduled in June
April 26, 2012
- IPV Vaccination Set to Begin in September; Adequate Supplies Expected
April 25, 2012
- Drug Discovery Support Network to Be Coordinated by NIBIO: 5-Year Strategy for Medical Innovation
April 25, 2012
- Medicoeconomic Assessment Should Initially Be Used in Reevaluating Existing Drugs: Dr Fukuda of NIPH
April 24, 2012
- HTA Should Be Used for NHI Drug Pricing, Not Reimbursement: Prof. Endo at DPJ Hearings
April 24, 2012
- PAFSC’s 2nd Committee Recommends Approval for Astellas’ Prostate Cancer Treatment, Japan's First IPV
April 23, 2012
- MHLW Aims to Begin IPV Vaccination in September: Health Minister Komiyama
April 23, 2012
- MHLW Issues Improvement Order to Pfizer for GMP Violation at US BVL Plant
April 20, 2012
- PAL Amendment: Proposal Emerges to Submit Legislation by Diet Members for Third Party Organization
April 19, 2012
- Discussions on Use of Cost-Effectiveness Assessments to Begin with Advanced but Costly Technologies: MED Director Suzuki
April 19, 2012
- DPJ Working Team to Hold Hearings on Cost-Effectiveness Assessments, Pricing of Long-Listed Drugs on April 20
April 19, 2012
- Risk Management Plans to Be Required from April 2013 to Strengthen Post-Marketing Safety Measures
April 18, 2012
- PAFSC’s 1st Committee to Discuss Approval for MTPC’s DPP-4 Inhibitor Tenelia at Meeting on April 27
April 17, 2012
- Members of Non-Partisan Study Group Support Generic Drug Use Requirement for Welfare Recipients
April 16, 2012
- CSIMC Expert Subcommittee to Begin Discussion on Long-Listed Drugs in June, Also Deliberate on Targets for Generic Products
April 13, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…